To maximize its cash runway while the Board conducts its review of strategic alternatives, Viracta has elected to close its ongoing pivotal Phase 2 clinical trial of Nana-val in relapsed/refractory ...

VERO BEACH, Florida, Dec. 26, 2024 (GLOBE NEWSWIRE) -- ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) ("ARMOUR” or the "Company”) today announced guidance on the January 2025 cash dividend for ...